Tags :Draupnir Holding

Samsung Biologics made recommended tender offer to acquire PolyPeptide at a price of CHF 44.31 per share. The tender offer values PolyPeptide’s equity at approximately CHF 1.46 billion. In connection with the deal, Lenz & Staehelin